Start Over

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1):First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Authors :: van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.
Internal medicine
Obstetrics and gynaecology
AII - Cancer immunology
CCA - Cancer Treatment and quality of life
Source :: van Breeschoten, J, Wouters, M W J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Blokx, W A M, ten Tije, B-J J, van der Veldt, A A M, Vreugdenhil, A, Boers-Sonderen, M J & van den Eertwegh, A J M 2021, ' Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1) : First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1) ', British Journal of Cancer, vol. 124, no. 10, pp. 1746 . https://doi.org/10.1038/s41416-021-01312-1, British Journal of Cancer, 124(10). Nature Publishing Group
Publication Year :: 2021
Abstract: Since the publication of this paper, the authors have noticed an error in the Abstract where the value for the 2-year overall survival

Details

Language :: English
ISSN :: 00070920
Database :: OpenAIRE
Journal :: van Breeschoten, J, Wouters, M W J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Blokx, W A M, ten Tije, B-J J, van der Veldt, A A M, Vreugdenhil, A, Boers-Sonderen, M J & van den Eertwegh, A J M 2021, ' Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1) : First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1) ', British Journal of Cancer, vol. 124, no. 10, pp. 1746 . https://doi.org/10.1038/s41416-021-01312-1, British Journal of Cancer, 124(10). Nature Publishing Group
Accession number :: edsair.dedup.wf.001..0f332eec4ea5af525571cd037be32f9c
Full Text :: https://doi.org/10.1038/s41416-020-01229-1)